The purpose of this study is to evaluate the effects of cranberry juice on central and peripheral blood pressure, indices of arterial stiffness, lipid and lipoprotein concentrations and size characteristics, and HDL function. The investigators hypothesize that the bioactive compounds in cranberry juice may elicit beneficial effects on blood pressure and arterial health, as well as LDL-C and HDL function.
The investigators propose to conduct a 2-period randomized, crossover, placebo-controlled study to evaluate the effect of cranberry juice on central and peripheral blood pressure, indices of arterial stiffness, lipid and lipoprotein concentrations and size characteristics, and HDL function. Eligibility requires non-smoking men and women to be 30 to 65 years of age with BMI greater than or equal to 18 and less than or equal to 39, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, triglycerides below 350 mg/dL, and have systolic blood pressure of 120 to 159 mmHg and/or diastolic blood pressure of 80 to 99 mmHg. Subjects will undergo randomized treatments including 500 mL/d cranberry juice beverage and 500 mL/d of a color and taste matched placebo beverage. The two 8 to 12 week treatment periods will be separated by an 8 week washout.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
47
16 ounces of 54% cranberry juice cocktail
Color, calorie, and taste matched beverage without cranberry bioactives
Penn State CRC
University Park, Pennsylvania, United States
Central Blood Pressure
Aortic (central) blood pressure measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Peripheral Blood Pressure
Peripheral blood pressure measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Efflux capacity of HDL
Ability to carry out reverse cholesterol transport measured using in vitro assay
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Augmentation Index
Augmentation index measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Pulse Wave Velocity
Pulse wave velocity measured using the SphygmoCor system
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
LDL-C
LDL-C values calculated using the Friedewald equation
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
LDL Particle Size
LDL particle size measured using a Vertical Auto Profile (VAP) Test
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Total Cholesterol
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Total cholesterol values determined by enzymatic procedures
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Triglycerides
Triglyceride values determined using enzymatic procedures
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
HDL-C
HDL-C will be estimated according to the modified heparin-manganese procedure
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Oxidized LDL (oxLDL)
Plasma concentrations of oxLDL will be measured using ELISA kits
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
Malondialdehyde (MDA)
MDA will be measured using the thiobarbituric acid reactive substances (TBARS) assay
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
High Sensitivity C Reactive Protein (hs-CRP)
hs-CRP will be measured by latex-enhanced immunonephelometry
Time frame: Change from baseline after 8 week treatments with cranberry and placebo
24-hr Ambulatory Blood Pressure
Time frame: Change from baseline after 8 week treatments with cranberry and placebo